Thomas Quertermous
Corporate Officer/Principal bei Stanford University
Profil
Thomas Quertermous is the founder of VIA Pharmaceuticals, Inc. which was founded in 2004.
He was also the founder of VIA Pharmaceuticals, Inc. in 2004 and held the title of Chief Scientific Officer in 2007.
Currently, he is a Professor at Stanford University since 1997.
He previously worked as a Director at CareDx, Inc. and Aviir, Inc. from 2006 to 2014.
He was also a Director-Cardiology Division & Professor at Vanderbilt University and an Independent Director at BioCardia, Inc. from 2002 to 2019.
Additionally, he was a Principal Laboratory Investigator at The General Hospital Corp.
He received his undergraduate degree from Grinnell College and his graduate and doctorate degrees from The University of Chicago.
Aktive Positionen von Thomas Quertermous
| Unternehmen | Position | Beginn |
|---|---|---|
| Stanford University | Corporate Officer/Principal | 01.01.1997 |
Ehemalige bekannte Positionen von Thomas Quertermous
| Unternehmen | Position | Ende |
|---|---|---|
| BIOCARDIA INC | Direktor/Vorstandsmitglied | 01.10.2019 |
Aviir, Inc.
 Aviir, Inc. Medical/Nursing ServicesHealth Services Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA. | Direktor/Vorstandsmitglied | 16.04.2014 |
VIA Pharmaceuticals, Inc. /Old/
 VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Gründer | 07.06.2007 |
| VIA PHARMACEUTICALS, INC. | Gründer | - |
BioCardia, Inc. /Old/
 BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Thomas Quertermous
| The University of Chicago | Doctorate Degree |
| Grinnell College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CAREDX, INC | Health Technology |
| VIA PHARMACEUTICALS, INC. | Health Technology |
| BIOCARDIA INC | Health Technology |
| Private Unternehmen | 4 |
|---|---|
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Health Technology |
Aviir, Inc.
Aviir, Inc. Medical/Nursing ServicesHealth Services Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA. | Health Services |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Health Technology |
